Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise
A trial is underway to assess the combination of adagrasib, pembrolizumab, and chemotherapy in KRAS G12C mutated NSCLC.
Phase III
Oncology / NSCLC
Status
Active
Sponsor
Mirati Therapeutics
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The ongoing trial of adagrasib combined with pembrolizumab and chemotherapy represents a significant advancement in the treatment of KRAS G12C mutated NSCLC. Positive results could enhance Mirati's competitive positioning and market share in the oncology sector.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any announcements regarding efficacy and safety data.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.